Polyion complex comprising PHD2 expression inhibiting substance

1. A pharmaceutical composition comprising, a polyion complex comprising a polyanionic substance as an active ingredient that suppresses the expression of PHD2, a polycation chargeable polymer, and glycosaminoglycan, which forms a ternary system complex of the polyion complex and glycosaminoglycan, wherein the polyanionic substance is selected from the group consisting of RNAi inducing nucleic acid against PHD2 or an expression vector thereof, antisense nucleic acid against PHD2 or an expression vector thereof, and a ribozyme against PHD2 or an expression vector thereof, and

the polycation chargeable polymer is a chargeable polymer represented by the following formula (III), a block copolymer represented by the following formula (I) or (II), or a salt thereof,

wherein,

R 10 is a hydroxy group, an oxybenzyl group or an NH—R 11 group, wherein R 11 is an optionally substituted straight chain or branched C 1-20 alkyl group,

R 1a and R 1b are each independently a hydrogen atom or an optionally substituted straight chain or branched C 1-12 alkyl group,

R 2a , R 2b , R 2c and R 2d are each independently a methylene group or an ethylene group,

R 3 is a hydrogen atom, a protecting group, a hydrophobic group or a polymerizable group,

R 4 is a hydroxy group, a protecting group or a group represented by —O—X 3 , —S—X 3 , —NH—X 3 , or a polymerization initiator residue of polypeptide, wherein X 3 is a primary, secondary or tertiary amine compound, or an amine compound residue comprising one or more groups derived from a quaternary ammonium salt, or a non-amine compound residue,

R 5a , R 5b , R 5c and R 5d are each independently a hydroxy group, an oxybenzyl group or an NH—(CH 2 ) a —X group, wherein a is an integer of 1-5, X is each independently a primary, secondary or tertiary amine compound, or an amine compound residue comprising one or more groups derived from a quaternary ammonium salt, or a non-amine compound residue,

the total of R 5a and R 5b or R 5c and R 5d contains at least two —NH—(CH 2 ) a —X 1 groups (wherein X 1 is (NH(CH 2 ) 2 ) 2 ) e —NH 2 , and e is an integer of 1-5),

R 6a and R 6b are each independently a hydrogen atom or protecting group, wherein the protecting group is selected from the group consisting of a Z group, a Boc group, an acetyl group and a trifluoroacetyl group,

L 1 and L 2 are linking groups,

m is an integer of 5-20,000,

n is an integer of 2-5,000,

y is an integer of 0-5,000,

z is an integer of 0-5,000, and y+z is not larger than n, and

each repeat unit in the above formulas may be present in the above specified order or may be present in a random order.

2. The pharmaceutical composition according to claim 1 , wherein the RNAi inducing nucleic acid is siRNA or an expression vector thereof.

3. The pharmaceutical composition according to claim 1 , wherein X is a group selected from the group consisting of —NH 2 , —NH—CH 3 , —N(CH 3 ) 2 and groups represented by the following formulas:

wherein,

X 2 is a hydrogen atom, a C 1-6 alkyl group or an amino C 1-6 alkyl group,

R 7a , R 7b and R 7c are each independently a hydrogen atom or a methyl group,

d1, d2 and d3 are each independently an integer of 1-5,

e1, e2 and e3 are each independently an integer of 1-5,

f is an integer of 0-15,

R 8a and R 8b are each independently a hydrogen atom or a protecting group, wherein the protecting group is selected from the group consisting of a Z group, a Boc group, an acetyl group and a trifluoroacetyl group, and

g is an integer of 0-15.

4. The pharmaceutical composition according to claim 1 , wherein L 1 or L 2 has a disulfide bond.

5. The pharmaceutical composition according to claim 1 , wherein the glycosaminoglycan is chondroitin sulfate or a salt thereof.

6. The pharmaceutical composition according to claim 1 , which is for the treatment or prophylaxis of an ischemic disease or artery disease.

7. The pharmaceutical composition according to claim 6 , wherein the ischemic disease or artery disease is selected from the group consisting of ischemic cardiac disease, myocardial infarction, cardiomyopathy, angina pectoris, unstable angina pectoris, coronary sclerosis, cardiac failure, arteriosclerosis obliterans, Buerger's disease, vascular injury, artery obstruction, arterial thrombosis, organ artery obstruction, aneurysm, ischemic brain diseases, ischemic lung disease and renal infarction.

8. A method for the treatment or prophylaxis of an ischemic disease or artery disease, comprising a step of administering the pharmaceutical composition according to claim 1 to a subject in need thereof.

9. The method for the treatment or prophylaxis according to claim 8 , wherein the ischemic disease or artery disease is selected from the group consisting of ischemic cardiac disease, myocardial infarction, cardiomyopathy, angina pectoris, unstable angina pectoris, coronary sclerosis, cardiac failure, arteriosclerosis obliterans, Buerger's disease, vascular injury, artery obstruction, arterial thrombosis, organ artery obstruction, aneurysm, ischemic brain disease, ischemic lung disease and renal infarction.